Skip to main content
Premium Trial:

Request an Annual Quote

PathoGenetix Raises $3.6M, Targeting $9.1M

NEW YORK (GenomeWeb News) – Sequencing technology firm PathoGenetix has raised $3.6 million, it said in a regulatory filing.

In the document filed with the US Securities and Exchange Commission on Tuesday, the Woburn, Mass.-based firm said it is targeting $9.1 million in the current offering. The type of securities being offered is in the form of equity. The company did not identify the investors or say how it plans to use the funding.

A company official did not respond to an e-mail requesting comment.

PathoGenetix develops products and applications based on its Genome Sequence Scanning technology, which was originally developed to detect biothreat pathogens in environmental samples. The company is exploring use of the technology for rapid bacterial identification and strain typing in food safety testing, industrial microbiology, and clinical diagnostics, and research.

In late September, it and Applied Math announced an agreement to integrate PathoGenetix's Resolution System and Applied Math's BioNumerics software.

Resolution is slated for a commercial launch during the third quarter of 2014 with assays to identify and serotype Salmonella and pathogenic E. coli strains, a company official told In Sequence recently.

PathoGenetix previously raised $11.5 million in a Series B round in 2011.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.